Moderna announced its intention to offer $2 billion in convertible senior notes due in 2029, with an option for initial purchasers to buy an additional $300 million. This move comes after the company's stock experienced a significant surge, reaching levels not seen since 2024, following successful late-stage trial results for its individualized cancer vaccine, intismeran, developed with Merck & Co. The vaccine, which combines with Keytruda, aims to prevent melanoma recurrence. This offering will allow Moderna to bolster its research and development efforts in oncology, particularly for its expanding cancer vaccine pipeline.
The announcement came shortly after Moderna's stock jumped 177% in a single day, adding nearly $45 billion to its market value. The stock's dramatic rise was triggered by the positive Phase 3 trial data for intismeran in melanoma, which analysts like RBC Capital Markets' Trung Huynh and TD Cowen's Tyler Van Buren called a "major win" and a "landmark moment." The vaccine, designed to target 34 unique protein flags on a patient's tumor, represents a "proof of principle that personalized cancer vaccines work," according to Marco Gerlinger, an oncologist.
Despite the immediate stock gains, some analysts cautioned that the market's reaction might be "overly optimistic." Evercore ISI's Cory Kasimov noted that the new valuation "already prices in substantially more conviction than the data disclosed thus far supports." Leerink Partners analyst Daina Graybosch suggested the expectations set by the stock surge would be "difficult to meet," particularly given the high manufacturing costs and the unique suitability of melanoma for this type of vaccine. However, the $2 billion offering demonstrates Moderna's confidence in leveraging its recent success to further its oncology initiatives and diversify revenue beyond its COVID-19 vaccines.
